Abstract
Host defense against pathogens relies on neutrophil activation. Inadequate neutrophil activation is often associated with chronic inflammatory diseases. Neutrophils also constitute a significant portion of infiltrating cells in chronic inflammatory diseases, for example, psoriasis and multiple sclerosis. Fumarates improve the latter diseases, which so far has been attributed to the effects on lymphocytes and dendritic cells. Here, we focused on the effects of dimethylfumarate (DMF) on neutrophils. In vitro, DMF inhibited neutrophil activation, including changes in surface marker expression, reactive oxygen species production, formation of neutrophil extracellular traps, and migration. Phagocytic ability and autoantibody-induced, neutrophil-dependent tissue injury ex vivo was also impaired by DMF. Regarding the mode of action, DMF modulates-in a stimulus-dependent manner-neutrophil activation using the phosphoinositide 3-kinase/Akt-p38 mitogen-activated protein kinase and extracellular signal-regulated kinase 1/2 pathways. For in vivo validation, mouse models of epidermolysis bullosa acquisita, an organ-specific autoimmune disease caused by autoantibodies to type VII collagen, were employed. In the presence of DMF, blistering in...Continue Reading
Citations
Dec 6, 2018·Journal of Clinical Medicine·Tonia WoodberryAnne Brüstle
Aug 6, 2016·Scientific Reports·Stephen Chu-Sung HuCheng-Che E Lan
May 10, 2017·PloS One·Tamara HoppenbrouwersMoniek P M de Maat
Oct 21, 2018·Nature Communications·Jacob Lauwring AndersenPoul Nissen
Mar 2, 2019·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Sudhir Kumar YadavSuhayl Dhib-Jalbut
May 24, 2019·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·Jonas Van DingenenRomain A Lefebvre
Apr 20, 2020·Liver International : Official Journal of the International Association for the Study of the Liver·Moris SanginetoHerbert Tilg
Mar 8, 2017·Experimental Dermatology·Ralf J Ludwig
Jul 25, 2017·The British Journal of Dermatology·J H O HoffmannE N Hadaschik
Mar 3, 2018·Frontiers in Immunology·Unni K SamavedamRalf J Ludwig
Apr 1, 2018·Experimental Dermatology·Jürgen BrückKamran Ghoreschi
Mar 4, 2018·Cold Spring Harbor Perspectives in Medicine·Simon Faissner, Ralf Gold
Nov 24, 2018·Frontiers in Medicine·Jinmin LeeAimee S Payne
Jun 18, 2020·Biomolecules·Ángel CoresJ Carlos Menéndez
May 20, 2016·Experimental Dermatology·Michael P SchönLuise Erpenbeck
May 29, 2018·Experimental Dermatology·Kevin J MillsJun Xu
Aug 30, 2018·Frontiers in Immunology·Melanie WannickMarkus Schwaninger
Mar 7, 2020·Pharmacological Reports : PR·Diaa RagabHanan S El-Abhar
Jan 23, 2020·ASN Neuro·Mikah S Brandes, Nora E Gray
Jul 2, 2020·International Journal of Molecular Sciences·Mirre De BondtSofie Struyf
Nov 11, 2017·Inflammation·Amanda Della GiustinaFabricia Petronilho
Jan 29, 2019·Frontiers in Medicine·Hiroshi KogaKatja Bieber
Dec 6, 2019·Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Società Italiana Di Dermatologia E Sifilografia·Emily F ColeRon J Feldman
Dec 31, 2020·Pharmaceuticals·Cara A Timpani, Emma Rybalka
Feb 21, 2021·The Journal of Investigative Dermatology·Paul SchilfChristian D Sadik
Dec 15, 2015·Experimental Dermatology·Eva Maria ValeskyMarkus Meissner
Oct 30, 2016·Journal of the European Academy of Dermatology and Venereology : JEADV·S MenziesA Lally
Apr 7, 2017·Journal of Neurochemistry·Cherie M SouthwoodAlexander Gow
Mar 20, 2021·Tissue Engineering. Part B, Reviews·Allison E Fetz, Gary L Bowlin
Apr 7, 2021·International Immunopharmacology·Jianfeng YuDan Liang
Mar 4, 2021·The British Journal of Dermatology·P J MorrisonU Mrowietz
Apr 4, 2021·ChemMedChem·Marcus J C Long, Yimon Aye
Nov 24, 2020·The Journal of Investigative Dermatology·Roberto MaglieMichael Hertl